(Q34593814)

3 August 2017

1 reference

title

Randomized controlled trials in schizophrenia: a critical perspective on the literature (English)

1 reference

3 August 2017

0 references

Gilbody S

1

1 reference

3 August 2017

Wahlbeck K

series ordinal

2

1 reference

3 August 2017

Adams C

series ordinal

3

1 reference

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

3 August 2017

9

1 reference

Acta Psychiatrica Scandinavica

inferred from page(s)

published in

1 reference

3 August 2017

105

1 reference

3 August 2017

4

1 reference

3 August 2017

243-251

1 reference

STREPTOMYCIN treatment of pulmonary tuberculosis

3 August 2017

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Controlled trials: the 1948 watershed

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Explanatory and pragmatic attitudes in therapeutical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Cost-effectiveness comparisons using "real world" randomized trials: the case of new antidepressant drugs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Pragmatic randomised controlled trials in psychiatry

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Content and quality of 2000 controlled trials in schizophrenia over 50 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Threats to applicability of randomised trials: exclusions and selective participation

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Practical problems in recruiting patients with schizophrenia into randomised controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Conventional antipsychotic medications for schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

The causes, consequences and detection of publication bias in psychiatry.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

To what extent should papers submitted from drug companies be published in medical journals?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Economic Analysis Alongside Clinical Trials: Revisiting the Methodological Issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

What are pragmatic trials?

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Why we need observational studies to evaluate the effectiveness of health care

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Outcomes research, PORTs, and health care reform

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Treatment research at the crossroads: the scientific interface of clinical trials and effectiveness research

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

21 January 2018

Please bypass the PORT.

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

Large-scale randomized evidence: large, simple trials and overviews of trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

CLINICAL TRIAL OF THE TREATMENT OF DEPRESSIVE ILLNESS. REPORT TO THE MEDICAL RESEARCH COUNCIL BY ITS CLINICAL PSYCHIATRY COMMITTEE

21 January 2018

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

7 January 2021

Alternative to the hospital: a controlled study

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

7 January 2021

Measurement of therapeutic response in schizophrenia. A critical survey

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

7 January 2021

Problems of using modelling in the economic evaluation of health care

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

7 January 2021

Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

7 January 2021

Reduced list costings: examination of an informed short cut in mental health research

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

7 January 2021

Should clinical trials with concurrent economic analyses be blinded?

1 reference

https://api.crossref.org/works/10.1034%2FJ.1600-0447.2002.00242.X

7 January 2021

10.1034/J.1600-0447.2002.00242.X

Identifiers

DOI

1 reference

3 August 2017

1 reference